BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10636205)

  • 1. The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review.
    Bustamante M; Stollman N
    J Clin Gastroenterol; 2000 Jan; 30(1):7-13. PubMed ID: 10636205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antisecretor treatment of digestive hemorrhage associated to peptic ulcer: an approximation to the available evidence].
    Bustamante Baléna M; Ponce García J
    Rev Clin Esp; 2004 Mar; 204(3):161-8. PubMed ID: 15025985
    [No Abstract]   [Full Text] [Related]  

  • 3. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
    Fitton A; Wiseman L
    Drugs; 1996 Mar; 51(3):460-82. PubMed ID: 8882382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
    Takeuchi K; Konaka A; Nishijima M; Kato S; Yasuhiro T
    J Gastroenterol Hepatol; 1999 Mar; 14(3):251-7. PubMed ID: 10197495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pantoprazole--a third proton pump inhibitor.
    Drug Ther Bull; 1997 Dec; 35(12):93-4. PubMed ID: 9614720
    [No Abstract]   [Full Text] [Related]  

  • 6. A review of treatment of duodenal and gastric ulcers--pantoprazole vs. omeprazole.
    Schepp W; Rehner M; Witzel L
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():53-7. PubMed ID: 8180295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding: a U.S. multicenter randomized, double-blind study.
    Jensen DM; Pace SC; Soffer E; Comer GM;
    Am J Gastroenterol; 2006 Sep; 101(9):1991-9; quiz 2170. PubMed ID: 16968504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
    Kromer W; Horbach S; Lühmann R
    Pharmacology; 1999 Aug; 59(2):57-77. PubMed ID: 10450061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitors.
    Grover JK; Vats V
    Trop Gastroenterol; 1999; 20(1):16-28. PubMed ID: 10464444
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.
    Javid G; Zargar SA; U-Saif R; Khan BA; Yatoo GN; Shah AH; Gulzar GM; Sodhi JS; Khan MA
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1236-43. PubMed ID: 19682194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Proton pump inhibitors in acute ulcer bleeding--what is evident?].
    Bohle W; Zoller WG
    Dtsch Med Wochenschr; 2000 Dec; 125(51-52):1571-4. PubMed ID: 11199449
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravenous proton pump inhibitors before endoscopy in bleeding peptic ulcer with high-risk stigmata: a multicentre comparative study.
    Andrews CN; Levy A; Fishman M; Hahn M; Atkinson K; Kwan P; Enns R
    Can J Gastroenterol; 2005 Nov; 19(11):667-71. PubMed ID: 16292361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of pantoprazole on non-variceal bleeding].
    Wu XP; He JR; Wang CL; Ling QH
    Hunan Yi Ke Da Xue Xue Bao; 2000 Aug; 25(4):361-2. PubMed ID: 12206002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
    Thomson AB
    Curr Gastroenterol Rep; 2000 Dec; 2(6):482-93. PubMed ID: 11079051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton-pump inhibitors: three of a kind?
    Bateman DN
    Lancet; 1997 Jun; 349(9066):1637-8. PubMed ID: 9186377
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy of controloc in the treatment of acid-dependent diseases].
    Chubenko SS; Gaĭdukov VO; Agibalov AN; Onishenko AV
    Lik Sprava; 2003 Dec; (8):103-4. PubMed ID: 14965022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor.
    Kaneko E; Hoshihara Y; Sakaki N; Harasawa S; Ashida K; Asaka M; Asaki S; Nakamura T; Kobayashi K; Kajiyama G; Ogawa N; Yao T; Muto Y; Nakazawa S; Takemoto T
    J Gastroenterol; 2000; 35(11):824-31. PubMed ID: 11085491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer.
    Gisbert JP; González L; Calvet X; Roqué M; Gabriel R; Pajares JM
    Aliment Pharmacol Ther; 2001 Jul; 15(7):917-26. PubMed ID: 11421865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of proton pump inhibitors.
    Der G
    Gastroenterol Nurs; 2003; 26(5):182-90. PubMed ID: 14603076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.